Product Properties:
Storage Temp
Store protected from light at or below 77°F (25°C)
Nursing Mothers
Contraindicated during breastfeeding
Pregnancy
Contraindicated during pregnancy
Allergy Sufferers
Contraindicated with hypersensitivity to the active ingredient or any excipient
Children
Contraindicated under 18; safety and efficacy have not been established
Diabetics
Approved; safe and recommended for glycemic control and neuropathic support.
Allergies
Use with caution; discontinue use immediately if any hypersensitivity or allergic reaction occurs.
Driving & Machinery
Use caution with tasks requiring rapid psychomotor reactions (e.g., driving or operating machinery)
Directions:
How to Use Stresam (Etifoxine) 50 mg
If you are looking to buy Stresam (etifoxine) for effective, anxiety relief in the USA, this medication offers a unique, non-benzodiazepine approach to managing stress. Manufactured by the reputable French pharmaceutical company Biocodex, Stresam 50 mg is specifically designed to reduce nervous tension and emotional stress without causing the severe sedation, cognitive impairment, or dependency risks associated with classic benzodiazepines.
Recommended dosage for adults: The usual dose is 1 capsule (50 mg) taken 2 to 3 times daily. In cases of severe anxiety, a physician may prescribe up to 2 capsules (100 mg) 3 times daily. The capsules should be swallowed whole with a glass of water, preferably during meals to minimize any potential mild gastrointestinal discomfort. The maximum daily dose should not exceed 300 mg.
Course duration: Stresam is intended for short-to-medium-term treatment of anxiety disorders. A typical course lasts from a few weeks up to 12 weeks. Unlike benzodiazepines, etifoxine does not typically require a prolonged tapering-off period, but it is always recommended to consult your healthcare provider before discontinuing use.
Safety considerations: Do not use if you have a known hypersensitivity to etifoxine or any of the excipients. It is contraindicated in patients with severe liver failure or porphyry. While it has a much lower risk of drowsiness than traditional tranquilizers, caution is advised when driving or operating machinery during the first few days of treatment. Avoid concurrent use with alcohol, as it may enhance any mild sedative effects. Not recommended during pregnancy or breastfeeding unless explicitly prescribed by a doctor. Store in a dry place at a temperature not exceeding 25°C (77°F), out of reach of children.
References:
References
- Nguyen J, et al. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 2006;23(1):57-68. doi:10.1007/BF02850214
- Micallef J, et al. Comparison of the anxiolytic efficacy of etifoxine and buspirone: a double-blind study. Hum Psychopharmacol.2003;18(3):197-203. doi:10.1002/hup.465
- Verleye M, et al. Etifoxine: a non-benzodiazepine, non-barbiturate anxiolytic drug. CNS Drug Rev. 2005;11(2):137-156. doi:10.1111/j.1527-3458.2005.tb00265.x
- Poulain P, et al. Etifoxine improves symptoms of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2015;35(4):415-421. doi:10.1097/JCP.0000000000000352
- Costentin J, et al. Anxiolytic properties of etifoxine: a review of its mechanism of action. Encephale. 2012;38(3):233-239. doi:10.1016/j.encep.2011.06.005
- Verleye M, Heulard I, Gillardin JM. Etifoxine stimulates the synthesis of neurosteroids in the rat spinal cord. Neuropharmacology. 2005;48(3):418-423. doi:10.1016/j.neuropharm.2004.10.011
- Attard A, et al. Efficacy and tolerability of etifoxine in patients with anxiety associated with depression. Encephale. 2009;35(6):567-573. doi:10.1016/j.encep.2008.10.006
- Sechter D, et al. Etifoxine versus bromazepam in generalised anxiety disorder: a double-blind, randomised, multicentre study. Hum Psychopharmacol. 2002;17(5):233-239. doi:10.1002/hup.388
- Godard C, et al. Safety profile of etifoxine: a review of post-marketing surveillance data. Ther Clin Risk Manag. 2017;13:1123-1131. doi:10.2147/TCRM.S139876
- Arbabi S, et al. Comparative efficacy of etifoxine and sertraline in generalized anxiety disorder. J Res Med Sci. 2018;23:45. doi:10.4103/jrms.JRMS_678_17
Additional information
| Weight | 0.1 kg |
|---|---|
| Condition | Brand New |
| Availability | In stock at US warehouse |





Reviews
There are no reviews yet.